The market moved sharply after a senior source said on Aug 4 that "there are no discussions" and "never was a deal," effectively closing the chapter on merger chatter. Traders responded immediately: AstraZeneca PLC (AZN) climbed 2.69% on the day as the takeover premium dissipated for the potential acquirer, while Bristol-Myers Squibb Co. (BMY) fell 3.43% as the merger-related uplift in its share price erased itself.
The timeline that mattered
- Aug 2 - The Financial Times reported preliminary merger talks; shares reacted sharply with AZN down about 9% and BMY up roughly 6% in pre-market trading.
- Aug 3 - RBC described the report as a "trial balloon," and AstraZeneca shareholders voiced unified opposition to the idea.
- Aug 4 - A senior source told Reuters there "never was a deal," effectively quashing the speculation for now.
AstraZeneca - a relief rally, not a turnaround
AstraZeneca shares, quoted at GBp 12,056 and up 2.69% on the session, staged a relief bounce after investor concern over an expensive and complex acquisition faded. That move follows a difficult stretch: the stock is down 8.21% over the past week and 16.60% in the last month, trading well below its 52-week high of GBp 15,730 and far beneath Bernstein's pre-episode Outperform target of GBp 20,200.
Shareholder opposition to the proposed premium was pronounced. The suggested price tag - a potential 40%-plus premium for a combined entity sized at around $400 billion - posed financing challenges, with BMO estimating debt capacity at only about $37 billion. Given those constraints, the market viewed the original merger math skeptically.
Despite the bounce, the stock still has meaningful ground to cover. Upcoming catalysts named in market commentary include tozorakimab Phase 3 data scheduled for presentation at ERS on Sep 5-6, AVANZAR lung cancer clinical results anticipated in the second half of 2026, and a filing for Datroway. Analysts and investors will also be watching management credibility and strategic direction closely.
Bull case - The removal of a merger discount and confidence in a deep pipeline with guidance above consensus support upside potential.
Bear case - Management credibility and clarity on capital allocation have been dented; even a denied "trial balloon" raises questions about strategic intent.
Bristol-Myers - premium evaporates, fundamentals persist
Bristol-Myers shares retreated to $63.63, down 3.43% on the day and back from a 52-week high of $68.10 reached just days before the initial report. Over the last month the stock is up 9.46%, and it remains up 38.78% over the past year. RBC's $64 price target sits close to the current level.
The company's recent operating results help explain why the rumor gained traction in the first place. In Q2, Bristol-Myers reported adjusted EPS of $2.04, beating the $1.61 consensus by 26.7%, and revenue of $12.97 billion versus an expected $11.71 billion. That operational momentum - including growth drivers such as Cobenfy in schizophrenia and Opdivo's broad reach - underpins bullish views on the stock.
Bull case - Strong earnings and product breadth support valuation at current levels.
Bear case - The looming loss of exclusivity for major products such as Eliquis and Opdivo, which together represent roughly half of total sales, constitutes a material revenue replacement challenge and is precisely the structural pressure that made deal speculation plausible.
What the denial means - and what it doesn't
The senior source's denial halts the immediate takeover narrative, but it leaves intact the fundamental questions that drove the market to consider a deal. Both management teams enter a period of scrutiny ahead of Q3 earnings season. Analysts are expected to press both companies on strategy during Q3 calls in the final week of October: AstraZeneca on expanding its U.S. revenue base beyond 42% of total sales, and Bristol-Myers on credible organic plans to offset losses from key drugs as exclusivities lapse.
In short, the market moved to reprice both shares after the rumor was disowned, but the structural challenges for each firm remain unaddressed by the denial itself.